In the landscape of modern drug discovery, a profound shift is occurring—not in the creation of new biological tools, but in the intelligent reappraisal of those already at our disposal. Digital pathology, once a niche convenience born of necessity during the global pandemic, has matured into a cornerstone of the "New Approach Methodologies" (NAMs) movement. By transforming glass slides into high-resolution pixel data, researchers are unlocking a vast, dormant repository of biological insight, effectively turning historical tissue archives into a goldmine that promises to spare thousands of animals from future testing.
The Paradigm Shift: From Disposable Slides to Data Assets
Traditionally, the life cycle of a pathology slide was linear and finite. A pathologist would examine a glass slide, document the pertinent findings in a static report, and consign the slide to long-term storage, often never to be touched again. This "one-way street" methodology treated tissue as a disposable resource.
“Before, the pathology endpoint was just a report,” explains Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories. “Now, you have the digitized slide, which is pixels. And pixels are data.”
This transition from physical artifact to digital asset is the engine behind the current transformation. When pathology images are digitized, they become searchable, shareable, and, most importantly, computable. By pairing these images with molecular measurements and granular pathology reports, researchers can train artificial intelligence models to recognize subtle biological patterns that would be invisible to the human eye. A single slide, once read and filed, can now be re-evaluated to answer entirely new scientific questions, effectively decoupling the tissue from the limitations of its original study.
Chronology of a Regulatory and Technological Evolution
The push toward replacing animal testing with digitized data has gained momentum through a series of key milestones:
- 2020–2021 (The Pandemic Catalyst): The sudden necessity of remote work forced a global adoption of digital pathology, proving that high-resolution scanning could maintain, and even enhance, diagnostic accuracy.
- 2022 (The FDA Modernization Act 2.0): A watershed moment in U.S. legislation, this act officially allowed for the use of non-animal testing methods to support Investigational New Drug (IND) applications.
- April 2024: Charles River Laboratories launched its "Alternative Methods Advancement Project," a strategic initiative aimed at scaling the use of digital tools and historical data to reduce reliance on live animal models.
- April 2025: The FDA released its comprehensive roadmap for reducing animal testing, prioritizing monoclonal antibodies and setting a clear trajectory toward making NAMs the industry standard within three to five years.
- September 2026: Further FDA regulatory updates solidified the framework for incorporating innovative, non-animal-based methodologies into safety assessments, signaling that the era of traditional animal-heavy testing is drawing to a close.
Virtual Control Groups and the Arithmetic of Ethics
One of the most immediate applications of this data-driven approach is the implementation of "virtual control groups." In standard toxicology, a significant percentage of animals are utilized purely as controls—subjects that receive no treatment—to establish a baseline for comparison.
By leveraging vast libraries of high-quality historical data, Charles River and other research organizations are finding that they can replace these concurrent control groups with matched, historical datasets. “Control animals are always a big fraction of every study,” Dr. Zuraw notes. By using robust, statistically validated historical controls, the total number of animals required per study is reduced through simple, ethical arithmetic.
However, the success of this model relies on strict rigorousness. Researchers must prove that the environmental conditions, genetic backgrounds, and handling protocols of historical subjects are perfectly aligned with current studies. The effort to build these "virtual" libraries is currently one of the most vital tasks in preclinical research, as it provides the foundation for widespread adoption.
Mining the "Formalin-Fixed" Archive
The industry standard for preserving tissue—Formalin-Fixed, Paraffin-Embedded (FFPE) blocks—represents a vast, largely untapped historical record. While these blocks were created for conventional staining, they contain the molecular signatures of how an organism responded to experimental drugs.
Previously, if a researcher developed a new hypothesis three years after an animal study concluded, the only way to test it was often to launch a new, parallel animal experiment. Today, researchers can return to the archived FFPE blocks, extract molecular information, and cross-reference it with the original dosing data.
The 2025 OECD guidance on omics analysis provides the framework for this, emphasizing that while storage quality is paramount, preserved tissue remains a viable source for gene expression and proteomic studies. This approach allows for a longitudinal view of drug interaction that was previously impossible without significant time and animal sacrifice.
The Implications: Virtual Staining and the "Snowball Effect"
Beyond re-mining old data, the field is moving toward "virtual staining." This cutting-edge process involves scanning unstained tissue sections and using software to generate the appearance of a stain. By bypassing the physical preparation of glass slides, labs can accelerate their throughput while reducing the physical footprint of their research operations.
Dr. Zuraw describes this as a potential "snowball effect." As researchers prove the utility of these digital methods in regulatory submissions, the infrastructure for digital pathology will become more standardized. Labs that were once hesitant to invest in the high-end scanners and cloud storage required for digital pathology will find the business case—driven by efficiency and regulatory compliance—impossible to ignore.
Challenges to Widespread Adoption
Despite the technological promise, significant hurdles remain. The transition requires a cultural shift within the scientific community. As Dr. Zuraw points out, "You still need enough early adopters to generate precedent." Regulatory bodies require evidence that these new methods are as reliable, if not more so, than the traditional methods they aim to replace.
This requires a period of "troubleshooting" where early adopters demonstrate consistency across multiple study types. Once these precedents are established, the path for smaller laboratories becomes clearer, allowing them to adopt digital methodologies without needing to reinvent the wheel.
Conclusion: A Future Built on Intelligence, Not Just Animals
The integration of digital pathology, AI, and historical data mining represents the most significant change in preclinical research in the last century. We are moving toward a future where the primary constraint on research is not the number of animals available for testing, but the depth of our ability to extract knowledge from the data we already hold.
By embracing the digital transformation, the pharmaceutical industry is not merely adopting new technology; it is fulfilling a moral and scientific mandate. As the FDA’s roadmap continues to unfold, the goal is clear: to make animal testing the exception rather than the default. Through the lens of digital pathology, the past is no longer a graveyard of used samples, but a foundational library that will help guide the safe, efficient, and ethical development of the next generation of life-saving medicines.
About the Author
